Immuron Ltd has released a press release.
Positive Results of IMM-124E in Acute Colitis Studies
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immuron
- Close of Recruitment of Phase II NASH Trial
- Appendix 4D - Half Year Report and Accounts - Dec 2016
- Immuron Completes Phase II NASH Clinical Trial Recruitment
- First Patient in Pediatric Fatty-Liver Phase II Trial
- NASH MOA Study commences with SanyalBio & Duke University
Later from Immuron
- IMC Form F1 - US Registration Statement (Prelim. Prospectus)
- Completion of Manufacturing of Drug Product for C-Diff Trial
- IMC Expands Agreement with US Army-3 Additional Therapeutics
- NASDAQ Listing on Hold Pending NASH Interim Analysis Results
- Immuron Secures $1.5M R&D Cash Advance Loan Funding
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron